Litigation Details for Arbutus Biopharma Corporation v. Moderna, Inc. (D. Del. 2022)
✉ Email this page to a colleague
Arbutus Biopharma Corporation v. Moderna, Inc. (D. Del. 2022)
| Docket | ⤷ Sign Up | Date Filed | 2022-02-28 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:1 Patent Infringement | Assigned To | Mitchell S. Goldberg |
| Jury Demand | Plaintiff | Referred To | |
| Parties | BAYH-DOLE COALITION | ||
| Patents | 8,058,069; 8,158,601; 8,492,359; 8,822,668; 9,364,435 | ||
| Attorneys | Emily DiBenedetto | ||
| Firms | Shaw Keller LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Arbutus Biopharma Corporation v. Moderna, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Arbutus Biopharma Corporation v. Moderna, Inc. (D. Del. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2022-02-28 | 1 | Complaint | them. The Asserted Patents are among them: a. U.S. Patent No. 8,058,069, “Lipid Formulations…deliver nucleic acid-based medicines: U.S. Patent Nos. 8,058,069 (Exhibit A), 8,492,359 (Exhibit B), 8,822,668… COUNT 1: INFRINGEMENT OF U.S. PATENT NO. 8,058,069 65. Paragraphs 1 through 64…Arbutus’s U.S. Patent No. 9,404,127 (“the ’127 Patent”), which, like the Asserted Patents, is directed …attempted to invalidate several of the patents before the United States Patent Case 1:22-cv-00252-MSG Document | External link to document |
| 2023-08-29 | 129 | Claim Construction Chart | the six patents that Plaintiffs have asserted Defendants infringe: U.S. Patent Nos. 8,058,069 (the “’…Petition for Inter Partes Review of U.S. Patent No. 8,058,069, IPR2019-00554 (Jan. 9, 2019) Petitioner…Petition for Inter Partes Review of U.S. Patent No. 8,058,069, IPR2019-00554, Exhibit 1008 (Jan. 2, 2019…Petition for Inter Partes Review of U.S. Patent No. 8,058,069, IPR2019-00554 (Jan. 9, 2019) Petitioner…Petition for Inter Partes Review of U.S. Patent No. 8,058,069, IPR2019-00554, Exhibit 1008, (Jan. 2, 2019 | External link to document |
| 2023-09-27 | 133 | COUNT 1: INFRINGEMENT OF U.S. PATENT NO. 8,058,069 65. Paragraphs 1 through …attempted to invalidate several of the patents before the United States Patent Case Case 1:22-cv-00252-…Arbutus’s patented technology, including the technology described and claimed in the Asserted Patents. Moderna…The United States Patent and Trademark Office duly and legally issued the ’069 Patent to one of Arbutus…incorporating Arbutus’s patented LNP delivery technology covered by the ’069 Patent, without authority or | External link to document | |
| 2022-05-06 | 17 | Exhibits A-B | that patent. 14. Further, Modema is a current licensee to U.S. Patent No. 8,058,069 ("…Regarding Patent And Copyright JUN 2020 Infringement 52.227-11 Patent Rights…Appeal from the United States Patent and Trademark Office, Patent Trial and Appeal Board in …it requires a license to its patents, including the '069 patent. Arbutus has not granted Modema…tiny-arbutus-biopharma-wins-patent- litigation-figh.aspx). 13. A finding that the '069 patent's claims | External link to document |
| 2023-12-21 | 174 | Redacted version of Plaintiffs' Letter Brief and Exhibits (D.I. 161) | regarding U.S. Patent Nos. 8,058,069 (“the ’069 patent”); 8,492,359 (“the ’359 patent”); 8,822,668 (…Contentions, Paragraph 4(c) Chart of U.S. Patent No. 8,058,069 at 1 (“ … (“the ’668 patent”); 9,364,435 (“the ’435 patent”); 9,504,651 (“the ’651 patent”); and 11,141,378 … the most basic discovery one can request in a patent case: samples of the accused product. Moderna has…embody the lipid ratios covered by Plaintiffs’ patents. 2 Each batch contains trillions of LNPs, each | External link to document |
| 2024-01-03 | 180 | Redacted Document | asserted patents, U.S. Patent Nos. 8,058,069 (the “’069 patent”), 8,492,359 (the “’359 patent”), 8,822,668…8,822,668 (the “’668 patent”), 9,364,435 (the “’435 patent”), and 11,141,378 (the “’378 patent”) (together, …two of the Lipid Composition Patents (the ’069 patent and the ’435 patent) in inter partes review (“IPR…in each of the Molar Ratio Patents. E.g., ’069 patent, claim 1, ’378 patent, claim 1; see also J.A. …Exxon Chem. Patents v. Lubrizol Corp., 64 F.3d 1553, 1558 (Fed. Cir. 1995), and the patent’s disclosure | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
